The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs.

ABSTRACT: Tumors of different molecular subtypes can show strongly deviating responses to drug treatment, making stratification of patients based on molecular markers an important part of cancer therapy. Pharmacogenomic studies have led to the discovery of selected genomic markers (e.g., BRAF^V600E), whereas transcriptomic and proteomic markers so far have been largely absent in clinical use, thus constituting a potentially valuable resource for further substratification of patients. To systematically assess the explanatory power of different -omics data types, we assembled a panel of 49 melanoma cell lines, including genomic, transcriptomic, proteomic, and pharmacological data, showing that drug sensitivity models trained on transcriptomic or proteomic data outperform genomic-based models

SUBMITTER: Rydenfelt M 

PROVIDER: S-EPMC6600015 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature